FERNISOLONE-P Drug Patent Profile
✉ Email this page to a colleague
When do Fernisolone-p patents expire, and when can generic versions of Fernisolone-p launch?
Fernisolone-p is a drug marketed by Ferndale Labs and is included in one NDA.
The generic ingredient in FERNISOLONE-P is prednisolone. There are eighty-eight drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the prednisolone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fernisolone-p
A generic version of FERNISOLONE-P was approved as prednisolone by ZHEJIANG XIANJU on May 2nd, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FERNISOLONE-P?
- What are the global sales for FERNISOLONE-P?
- What is Average Wholesale Price for FERNISOLONE-P?
Summary for FERNISOLONE-P
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 94 |
| Patent Applications: | 4,839 |
| DailyMed Link: | FERNISOLONE-P at DailyMed |
US Patents and Regulatory Information for FERNISOLONE-P
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferndale Labs | FERNISOLONE-P | prednisolone | TABLET;ORAL | 083941-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for FERNISOLONE-P
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| LE VET B.V. | Equisolon | Prednisolone | EMEA/V/C/002382 Alleviation of inflammatory and clinical parameters associated with recurrent airway obstruction (RAO) in horses, in combination with environmental control. |
Authorised | no | no | no | 2014-03-12 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
